BRAF and metastatic melanoma: There was only one published cost-effectiveness comparison between dabrafenib plus trametinib and vemurafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, which was in a Swiss setting [20].